Trial · NCT01243424
Results by group58
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 58
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| The First 3-point Major Adverse Cardiovascular Events (3P-MACE) | Linagliptin | 20.7 | Events/ 1000 patients-years | ||
| The First 3-point Major Adverse Cardiovascular Events (3P-MACE) | Glimepiride | 21.2 | Events/ 1000 patients-years | ||
| The First 4-point (4P)- MACE | Linagliptin | 23.4 | Events/ 1000 patients-years | ||
| The First 4-point (4P)- MACE | Glimepiride | 23.7 | Events/ 1000 patients-years | ||
Percentage of Participants Taking Trial Medication at Trial End, Maintained Glycaemic Control (HbA1c ≤7.0%) Without Need for Rescue Medication, Without >2% Weight Gain, and Without Moderate/Severe Hypoglycaemic Episodes During Maintenance Phase | Linagliptin | 16.0 | 95% Confidence Interval 14.7 to 17.3 | Percentage of participants (%) | |
Percentage of Participants Taking Trial Medication at Trial End, Maintained Glycaemic Control (HbA1c ≤7.0%) Without Need for Rescue Medication, Without >2% Weight Gain, and Without Moderate/Severe Hypoglycaemic Episodes During Maintenance Phase | Glimepiride | 10.2 | 95% Confidence Interval 9.1 to 11.3 | Percentage of participants (%) | |
Percentage of Participants Who Were on Trial Medication at Trial End, Maintained Glycaemic Control (HbA1c ≤7.0%) Without Need for Rescue Medication, and Without >2% Weight Gain During Maintenance Phase | Linagliptin | 17.4 | 95% Confidence Interval 16.1 to 18.8 | Percentage of participants (%) | |
Percentage of Participants Who Were on Trial Medication at Trial End, Maintained Glycaemic Control (HbA1c ≤7.0%) Without Need for Rescue Medication, and Without >2% Weight Gain During Maintenance Phase | Glimepiride | 14.1 | 95% Confidence Interval 12.9 to 15.4 | Percentage of participants (%) | |
| Percentage of Participants With the Occurrence of at Least One Event of 3P-MACE | Linagliptin | 11.8 | 95% Confidence Interval 10.7 to 13.0 | Percentage of participants (%) | |
| Percentage of Participants With the Occurrence of at Least One Event of 3P-MACE | Glimepiride | 12.0 | 95% Confidence Interval 10.9 to 13.2 | Percentage of participants (%) | |
| Percentage of Participants With the Occurrence of at Least One Event of 4P -MACE | Linagliptin | 13.2 | 95% Confidence Interval 12.0 to 14.4 | Percentage of participants (%) | |
| Percentage of Participants With the Occurrence of at Least One Event of 4P -MACE | Glimepiride | 13.3 | 95% Confidence Interval 12.2 to 14.6 | Percentage of participants (%) | |
| Percentage of Participants With Occurrence of Any of the Components of the Composite Endpoint of All Adjudication-confirmed Events | Linagliptin | 17.1 | 95% Confidence Interval 15.8 to 18.5 | Percentage of participants (%) | |
| Percentage of Participants With Occurrence of Any of the Components of the Composite Endpoint of All Adjudication-confirmed Events | Glimepiride | 17.8 | 95% Confidence Interval 16.4 to 19.2 | Percentage of participants (%) | |
| Time to First Occurrence of Any of the Components of the Composite Endpoint of All Adjudication-confirmed Events | Linagliptin | 31.1 | Events/ 1000 patients-years | ||
| Time to First Occurrence of Any of the Components of the Composite Endpoint of All Adjudication-confirmed Events | Glimepiride | 32.4 | Events/ 1000 patients-years | ||
| Change From Baseline to Final Visit in Hemoglobin A1c (HbA1c) | Linagliptin | 0.06 | Standard Error 0.02 | Percentage glycosylated hemoglobin (%) | |
| Change From Baseline to Final Visit in Hemoglobin A1c (HbA1c) | Glimepiride | 0.15 | Standard Error 0.02 | Percentage glycosylated hemoglobin (%) | |
| Change From Baseline to Final Visit in Fasting Plasma Glucose (FPG) | Linagliptin | 12.4 | Standard Error 0.9 | Milligram/ deciliter (mg/dL) | |
| Change From Baseline to Final Visit in Fasting Plasma Glucose (FPG) | Glimepiride | 19.7 | Standard Error 0.9 | Milligram/ deciliter (mg/dL) |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01243424/results